Six Years in Federal Prison: What the Paradigm Peptides Case Means for Med Spas and Wellness Clinics
Six Years in Federal Prison: What the Paradigm Peptides Case Means for Med Spas and Wellness Clinics
By Kate Dee, MD — Founder, Glow Medispa | Author, Med Spa Mayhem
Fifty-four thousand customers. Eighty countries. Forged laboratory certificates. Bottles labeled as “SARMs” that, when the government finally tested them, turned out to contain testosterone — a controlled substance. And one customer, a 32-year-old marketing consultant named Dan Murphy, who took what he thought was a legal muscle-building compound and ended up with steroid-induced psychosis, paranoid delusions, and suicidal thoughts.
On July 30, 2026, a federal judge in the Northern District of Indiana handed down the bill for all of it. Matthew Kawa, the owner of Paradigm Peptides, was sentenced to 70 months — just short of six years — in federal prison. His sister and employee, Jennifer L. Stechkober, received 16 months. Both will serve a year of supervised release afterward, and both are on the hook, jointly and severally, for $78,317.52 in restitution. Kawa alone faces a $5 million forfeiture judgment tied to what prosecutors say he made off the business.
This is not a med spa case. Paradigm Peptides was an online retailer, not a licensed medical practice. But I want every physician, nurse practitioner, and wellness operator reading this to sit with the details, because the products at the center of this case — peptides, SARMs, hCG — are the same products showing up on treatment menus at longevity clinics and med spas across the country right now. The gap between “we sell it online” and “we offer it in the treatment room” is smaller than you think, and the federal government has just shown exactly what it is willing to do when that gap gets exploited.
What the government said happened
According to the U.S. Attorney’s Office for the Northern District of Indiana, Paradigm Peptides — legally known as Paradigm R.E. LLC — sold peptides, human chorionic gonadotropin (hCG), selective androgen receptor modulators (SARMs), and other unapproved drugs through an online storefront that shipped out of Michigan City, Indiana, from April 2019 to March 2024. By the time investigators shut it down, the business had reached roughly 54,000 unique customers in all 50 states and more than 80 countries.
None of it happened in the dark. The FDA sent Paradigm warning letters in 2020 and again in 2022, telling Kawa directly that he was marketing and selling unapproved new drugs. He kept selling. Kawa and Stechkober pleaded guilty on December 10, 2025, to introducing unapproved new drugs into interstate commerce with intent to defraud and mislead; Kawa separately pleaded guilty to illegally importing merchandise into the United States.
At sentencing, U.S. District Judge Cristal C. Brisco reportedly told Kawa he had left behind “an incredible trail of harm” and had ignored repeated warnings from regulators before finally being stopped. Officials from the FDA’s Office of Criminal Investigations and the U.S. Postal Inspection Service, who investigated the case together, said the sentence reflects a broader commitment to holding accountable anyone who traffics in unapproved drugs and abuses the mail system to reach patients directly.
The forged certificates and the testosterone in the bottle
The mechanics of the fraud are what should really get every med spa operator’s attention. Paradigm told customers its products were manufactured in the United States and independently lab-tested for purity — claims of 99% purity were common. In reality, prosecutors say the products were sourced from China, India, and other countries, and Kawa admitted that the laboratory certificates backing up those purity claims had been forged.
Then there is the testosterone problem. Federal investigators tested six of Paradigm’s compounds that were designed to mimic testosterone — sold and labeled as SARMs — and every single one actually contained testosterone, a Schedule III controlled substance. Kawa admitted in his plea that he never tested the SARM products his business sold. Layered on top of that was the “research use only” label many of these products carried, a disclaimer meant to signal the product isn’t for human consumption. Kawa admitted he knew Paradigm’s products were being marketed and sold for human consumption anyway. The label was decoration, not a legal shield, and prosecutors treated it that way.
What that meant for a real patient
Dan Murphy is not a plaintiff’s attorney’s hypothetical. He is a 32-year-old marketing consultant who told CBS News he started on Paradigm SARMs expecting a performance edge and instead got grandiose thinking that “descended into a deep paranoia,” cystic acne, insomnia, and compulsive exercise. A medical expert later diagnosed him with steroid-induced psychosis. Independent testing of his own bottle confirmed what the federal testing found industry-wide: testosterone, not a SARM. Murphy has said publicly that the experience brought him to the point of wanting to die. He is now pursuing civil litigation against the company.
That is the actual cost of a forged certificate of analysis and a “research use only” sticker slapped on a product marketed for human use. It is not an abstraction. It is a patient in a psychiatric crisis because nobody verified what was actually in the vial.
Why this is not just a peptide-seller problem
Paradigm Peptides sold directly to consumers, which makes the fact pattern clean. Most med spas, wellness practices, and longevity clinics are one step removed — you are not importing raw material from a supplier in China and repackaging it yourself. But the underlying exposure is the same set of questions: Where did this product actually come from? Is it FDA-approved, or is there a lawful compounding pathway that covers it? Is the purity and quality documentation real? And is the “research use only” language on a bulk peptide something you’re treating as a legal formality while actually using the product on patients?
This case did not happen in isolation. A separate federal case out of Utah, announced April 1, 2026, involved allegations that an osteopathic physician obtained non-FDA-approved peptides from China, added his own labels before using them in his clinic, and sold them to more than 200 patients — the indictment named tirzepatide, semaglutide, BPC-157, TB-500, and NAD+ specifically. And FDA briefing documents released in July 2026, addressing seven peptide-related bulk drug substances proposed for the Section 503A Bulks List, recommended against adding the free base and acetate forms of BPC-157 and TB-500 to that list. In plain terms: for some of the most popular peptides on med spa menus right now, there is currently no clear, FDA-endorsed pathway for a compounding pharmacy to use them under 503A. If your supplier or your compounding relationship is treating that as settled, it isn’t.
What to actually do about it
If your practice offers or facilitates access to peptides, SARMs, hCG, or adjacent products — or if you rely on a supplier, compounding pharmacy, or telehealth partner who does — here is where I would start this week:
•Verify product sourcing, manufacturing origin, and supplier documentation before you use or dispense anything. “Made in the USA” and “third-party tested” are claims, not facts, until you have seen the underlying paperwork yourself.
•Confirm the FDA approval status of the product, or the specific compounding pathway (503A or 503B) that applies to it. “Everyone else is offering it” is not a legal basis.
•Review the actual product label and ingredient information against what is being supplied. Paradigm’s SARMs were testosterone. Trust, but verify — with your own testing where possible.
•Validate laboratory testing, purity claims, and quality documentation independently rather than accepting a certificate of analysis at face value. Paradigm’s were forged.
•Treat any “research use only” product as exactly that. If it is being administered to a patient, it is not research use, and the label will not protect you or your practice.
•Make sure the practitioner authority for prescribing, dispensing, and administering these products is clearly established and documented under your state’s law.
•Audit your own marketing and any cross-state sales. Paradigm sold nationwide from one small storefront in Indiana; state-specific licensure and prescribing requirements do not disappear because a sale happens online.
What to watch next
The criminal case against Kawa and Stechkober is over. The broader regulatory picture is not. FDA’s review of the 503A Bulks List is ongoing, the Utah physician case is still working through the courts, and the tone from both FDA and USPIS at this sentencing — explicitly framed around continued enforcement — suggests this will not be the last peptide-related prosecution. Expect more FDA guidance, more warning letters, and more scrutiny of exactly the questions raised above.
A final word
I know peptides are popular right now, and I know the margins can be good. But “I didn’t know what was actually in the vial” has never held up as a defense, and it will not start now. Matthew Kawa got two FDA warning letters and kept going for years before the government finally shut him down with a criminal case. Do not be the med spa or wellness clinic that finds out the hard way — through a patient’s psychiatric hospitalization, a state board complaint, or a federal indictment — that your supplier’s paperwork was as fictional as Paradigm’s was.
— Kate Dee, MD
Sources & further reading
Illinois Man and Indiana Woman Sentenced Respectively to 70 Months and 16 Months in Prison For Selling Unapproved Drugs in Interstate Commerce (U.S. Attorney's Office, Northern District of Indiana, July 30, 2026) — https://www.justice.gov/usao-ndin/pr/illinois-man-and-indiana-woman-sentenced-respectively-70-months-and-16-months-prison
United States v. Matthew Kawa (U.S. Attorney's Office, Northern District of Indiana) — https://www.justice.gov/usao-ndin/united-states-v-matthew-kawa
Judge sentences peptide vendor to nearly 6 years in prison for “an incredible trail of harm” (CBS News, July 30, 2026) — https://www.cbsnews.com/news/peptides-seller-prison-sentence-unapproved-drugs/
Man speaks out after peptide vendor's sentencing: “I wanted to die” (CBS News, July 30, 2026) — https://www.cbsnews.com/video/man-speaks-out-after-peptide-vendors-sentencing-i-wanted-to-die/
Peptide Company Owner Sentenced To Nearly Six Years For Selling Adulterated Products (VINnews, August 2, 2026) — https://vinnews.com/2026/08/02/peptide-company-owner-sentenced-to-nearly-six-years-for-selling-adulterated-products/
Brother and Sister Sentenced for Selling Unapproved Drugs to 52,000 for $5 Million (McHenry County Blog, August 1, 2026) — https://www.mchenrycountyblog.com/2026/08/01/brother-and-sister-sentenced-for-selling-unapproved-drugs-to-52000-for-5-million/
Peptide Seller Gets Nearly Six-Year Federal Sentence Over Unapproved Drug Sales (Sarah Wedel, DNP, FNP-BC, AGNP-BC, SpaKinect, August 4, 2026) — https://www.spakinect.com/news/federal-peptide-seller-unapproved-drug-sentence
FDA briefing documents address seven peptide-related bulk drug substances proposed for the 503A Bulks List (SpaKinect News, July 2026) — https://www.spakinect.com/news/fda-briefing-documents-seven-peptides-503a-bulks-list
Utah physician indicted over non-FDA-approved peptides sourced from China (SpaKinect News, April 1, 2026) — https://www.spakinect.com/news/utah-physician-non-fda-approved-peptides-indictment
